Issue

Vol. 66 No. 5: Issue 5

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

The combination therapy with esomeprazole and flupenthixol/melitracen in symptom improvement of erosive gastritis complicated with negative feelings compared with Esomeprazole alone

https://doi.org/10.14715/cmb/2020.66.5.3
Lidan Hu
1. General Medicine Ward, Gele Mountain Hospital of Chongqing Mental Health Center, Chongqing,400036, China
Liandong Shen
Department of anus & intestine surgery, Affiliated Hospital of Yan'an University, Yan'an, Shanxi, China
Dechuan Li
3. Department of general surgery, Central Hospital of Chongqing Three Gorges, Bai an Branch, Chongqing, China.
Min Huang
Department of general practice, Central Hospital of Chongqing Three Gorges, Bai an Branch, Chongqing, China.
Xingpeng Xiao
Department of anaesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Shengquan Chen
Department of general surgery, Guanvun County People's Hospital of Jiangsu Province, Lianyungang, Jiangsu, China

Corresponding Author(s) : Shengquan Chen

wanghuanqian1988@gmail.com

Cellular and Molecular Biology, Vol. 66 No. 5: Issue 5

Abstract

The purpose of this study was to evaluate the co-prescription efficacy of esomeprazole and flupenthixol/melitracen relative to that of solitary esomeprazole on erosive gastritis complicated with negative feelings. 140 erosive gastritis patients complicated with negative feelings enrolled in the present study. Seventy cases in the control group took esomeprazole, and 70 cases in the observation group received esomeprazole plus flupenthixol/Melitracen, both for 4 weeks. We gastroscopically checked the clinical symptoms, mucosal erosion, PGE2 and MDA levels in gastric mucosa, anxiety, depression, and recurrence before and after treatment in the groups. After treatment, the observation group had lower scores of clinical symptoms, mucosal erosions, Hamilton Depression Rating Scale (HAMD), and Hamilton Depression Rating Scale (HAMA) than the control group (p<0.05); as well, the observation group showed higher PGE2 and lower MDA levels than the control group (p<0.05); during six months of follow-up (100% follow-up rate), 16 and 34 recurrent cases occurred, respectively, in the observation and control groups (p<0.05).  Co-prescription of esomeprazole and flupenthixol/melitracen improved the clinical symptoms and mucosal erosions, relieved negative feelings and reduced the recurrence rate. The efficacy of the co-prescription is higher than that of the solitary prescription.

Keywords

Gastric mucosa mucosal erosion PGE2 MDA negative feelings
Hu, L., Shen, L., Li, D., Huang, M., Xiao, X., & Chen, S. (2020). The combination therapy with esomeprazole and flupenthixol/melitracen in symptom improvement of erosive gastritis complicated with negative feelings compared with Esomeprazole alone. Cellular and Molecular Biology, 66(5), 15–19. https://doi.org/10.14715/cmb/2020.66.5.3
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Procaccio F, Stocchetti N, Citerio G, Berardino M, Beretta L, Della Corte F, et al. Guidelines for the treatment of adults with severe head trauma (part I). Initial assessment; evaluation and pre-hospital treatment; current criteria for hospital admission; systemic and cerebral monitoring. J Neurosurg Sci 2000; 44:1-10.
  2. Farthing MJ, Fairclough PD, Hegarty JE, Swarbrick ET, Dawson AM. Treatment of chronic erosive gastritis with prednisolone. Gut. 1981; 22(9):759-62.
  3. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 2001; 49(3):347-53.
  4. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. New Engl J Med 2001; 345(11):784-9.
  5. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterol 2008;134(4):945-52.
  6. Brunner G，Athmann C，Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther 2012; 36: 37-47．
  7. Schistosomes, Liver Flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. IARC Monogr Eval Carcinog Risks Hum, Lyon, 1994, pp. 7-14.
  8. Jankowski J. Helicobacter pylori infection and gastric cancer. BMJ 1991; 302:1534.
  9. Iacono LA. Exploring the guide lines for the management of severe head injury. J Neurosci Nurs 2000; 32:54-60.
  10. Juul N, Morris GF, Marshall SB, Marshall LF. Intracranial hypertension and cerebral perfusion pressure: influence on neurological deterioration and outcome in severe head injury. The executive committee of the international selfotel trial. J Neurosurg 2000; 92:1-6.
  11. Dixon MF. Pathophysiology of Helicobacter pylori infection. Scand J Gastroenterol Suppl 1994; 201:7-10.
  12. Sahoo N, Gu M, Zhang X, Raval N, Yang J, Bekier M, Calvo R, Patnaik S, Wang W, King G, Samie M. Gastric acid secretion from parietal cells is mediated by a Ca2+ efflux channel in the tubulovesicle. Dev Cell 2017; 41(3):262-73.
  13. Baratta VM, Di Renzo C, Ollodart J, Geibel J, Barahona MJ. Perspectives in Pursuit of the Parietal Cell-An Evolution of Scientific Methodology and Techniques. Front Physiol 2019; 10:1497.
  14. Engevik AC, Kaji I, Goldenring JR. The physiology of the gastric parietal cell. Physiol Rev 2019 Oct 31.
  15. van Wering HM, Benninga MA. Histamine-2 Receptor Antagonist in the Treatment of Gastroesophageal Reflux Disease. In Esophageal and Gastric Disorders in Infancy and Childhood 2017 (pp. 987-994). Springer, Berlin, Heidelberg.
  16. Landa ST, Dumon KR, Dempsey DT. Anatomy and Physiology of the Stomach and Pylorus. InThe SAGES Manual of Foregut Surgery 2019 (pp. 49-64). Springer, Cham.
  17. Sakai H, Fujii T, Takeguchi N. Proton-Potassium (H+/K+) ATPases: Properties and Roles in Health and Diseases. InThe Alkali Metal Ions: Their Role for Life 2016 (pp. 459-483). Springer, Cham.
  18. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct 1;64(10):935-51.
  19. Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole. Drugs: a review of its use in management of acid-related disorders. 2002; 62(10):1503-38.
  20. Sachs G, Shin JM, Howden CW. The clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23:2-8.
  21. Retief M, Chiliza B, Phahladira L, Emsley R, Asmal L. Prolactin, flupenthixol decanoate and first episode schizophrenia–clinical and laboratory correlates. Metab Brain Dis 2019; 34(6):1679-87.
  22. Yan XJ, Li WT, Chen X, Wang EM, Liu Q, Qiu HY, Cao ZJ, Chen SL. Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients. World J Gastroenterol 2015; 21(15):4652.
  23. Zhang HL, Guo ZN, Yang G, Yang L, Han K, Wu J, Xing Y, Yang Y. Compromised cerebrovascular modulation in chronic anxiety: evidence from cerebral blood flow velocity measured by transcranial Doppler sonography. Neurosci Bull 2012; 28(6):723-8.
  24. Corsi-Zuelli FM, Brognara F, Quirino GF, Hiroki CH, Fais RS, Del-Ben CM, Ulloa L, Salgado HC, Kanashiro A, Loureiro CM. Neuroimmune interactions in schizophrenia: focus on vagus nerve stimulation and activation of the alpha-7 nicotinic acetylcholine receptor. Front Immunol 2017; 8:618.
  25. Baker E, Lui F. Neuroanatomy, Vagal Nerve Nuclei (Nucleus Vagus). In StatPearls [Internet] 2019 Jul 29. StatPearls Publishing.
  26. Anwar IJ, Miyata K, Zsombok A. Brain stem as a target site for the metabolic side effects of olanzapine. J Neurophysiol 2016; 115(3):1389-98.
  27. Rudorfer MV, Young RC. Anticholinergic effects and plasma desipramine levels. Clin Pharmacol Ther 1980; 28(5):703-6.
  28. Fujishiro J, Imanishi T, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol 2002; 454(2-3):183-8.
  29. Johnsson C, Lundborg P, Welin"Fogelberg I. Interaction studies between three antidepressant drugs (clomipramine, imipramine and zimelidine) and noradrenaline, tyramine and vagal stimulation on the heart rate and blood pressure in dogs. Acta Pharmacol Toxicol 1979; 45(3):192-7.
  30. Ghia JE. The vagus nerve: A modulator of intestinal inflammation. Autonomic Neuroscience: Basic Clin 2013; 177(1):43.
  31. Kodadek LM, Jones C. Stress Gastritis and Stress Ulcers: Prevention and Treatment. Surg Crit Care Ther 2018; 231-239. Springer, Cham.
  32. Goderska K, Pena SA, Alarcon T. Helicobacter pylori treatment: antibiotics or probiotics. Appl Microbiol Biotechnol 2018; 102(1):1-7.
  33. Fujiwara S, Morita Y, Toyonaga T, Kawakami F, Itoh T, Yoshida M, et al．A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection. J Gastroenterol 2011; 46:595-602.
  34. Chambers IR, Treadwell L, Mendelow AD. The cause and incidence of secondary insults in severe head-injured adults and children. Br J Neurosurg 2000; 14:424-31.
  35. Sarrafzadeh AS, Peltonen EE, Kaisers U, Küchler I, Lanksch WR, Unterberg AW. Secondary insults in severe head injury--do multiply injured patients do worse? Crit Care Med 2001; 29:1116-23.
  36. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol 1993; 88:1801-2.
  37. Morii M, Takata H, Fujisaki H, Takeguchi N. The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlated with the rate of acid-activation of the inhibitor. Biochem Pharmacol 1990; 39:661-7.
  38. Hirai M1, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J Gastroenterol 1995; 30:461-4.
  39. Menzel M, Soukup J, Henze D, Clausen T, Marx T, Hillman A, et al. Brain tissue oxygen monitoring for assessment of autoregulation: preliminary results suggest a new hypothesis. J Neurosurg Anesthesiol 2003; 15:33-41.
  40. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13:27-36.
  41. Takeuchi K, Amagase K. Roles of cyclooxygenase, prostaglandin E2 and EP receptors in mucosal protection and ulcer healing in the gastrointestinal tract. Curr Pharmaceutic Design. 2018; 24(18):2002-11.
  42. Brzozowski T, Magierowska K, Magierowski M, Ptak-Belowska A, Pajdo R, Kwiecien S, Olszanecki R, Korbut R. Recent advances in the gastric mucosal protection against stress-induced gastric lesions. Importance of renin-angiotensin vasoactive metabolites, gaseous mediators and appetite peptides. Curr Pharmaceutic Design 2017; 23(27):3910-22.
  43. Oskouei Z, Akaberi M, Hosseinzadeh H. A glance at black cumin (Nigella sativa) and its active constituent, thymoquinone, in ischemia: a review. Iranian J Basic Med Sci 2018; 21(12):1200.
  44. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal 2014; 20(7):1126-67.
  45. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Modern Genetics J 2020; 15(2): 75-92.
  46. Röhss K, Wilder-Smith C, Nauclér E, Jansson L. Esomeprazole 20mg provides more effective intragastric Acid control than maintenance-dose rabeprazole, lansoprazole or pantoprazole in healthy volunteers. Clin Drug Investig 2004; 24:1-7.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1091 Download : 556